To determine whether GAG levels affect carboplatin activity, we generated GAG-deficient ES2 ovarian cancer cells using CRISPR-mediated knockout of xylosyltransferases XYLT1 and XYLT2, the enzymes responsible for the initial step in GAG biosynthesis. The gene discussed is XYLT2; the disease is ovarian carcinoma.